Related Experiment Videos
Immune enhancement in mice by ara-A
Journal of Immunology (Baltimore, Md. : 1950)
|February 1, 1983
Summary
Vidarabine (ara-A) enhances immune responses in mice, boosting both humoral and cell-mediated immunity. This antiviral agent may significantly impact host resistance against infections like Cryptococcus neoformans.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- The antiviral agent Vidarabine (ara-A) is known to affect cellular processes.
- Understanding its impact on the immune system is crucial for its therapeutic application.
Purpose of the Study:
- To investigate the effects of Vidarabine (ara-A) on murine immune responses.
- To explore the potential of ara-A as an immunomodulatory agent in the context of antiviral therapy.
Main Methods:
- Administration of single, non-toxic doses of Vidarabine (ara-A) to mice.
- Assessment of humoral and cell-mediated immune responses to defined antigens.
- Evaluation of survival rates in experimental Cryptococcus neoformans infections.
Main Results:
- Vidarabine (ara-A) significantly stimulated both humoral and cell-mediated immune responses in a dose-dependent manner.
- The efficacy of ara-A varied among different mouse strains.
- Ara-A administration resulted in altered survival rates during Cryptococcus neoformans infections, indicating an impact on host resistance.
Conclusions:
- Vidarabine (ara-A) possesses immunostimulatory properties that can enhance immune responses.
- The observed effects on host resistance suggest potential clinical significance for ara-A as an antiviral therapeutic.
- The mechanism of action likely involves toxicity to suppressor cells, leading to immune potentiation.